Cargando…
Correction: Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314609/ https://www.ncbi.nlm.nih.gov/pubmed/37399365 http://dx.doi.org/10.1136/rmdopen-2022-002830corr1 |
Ejemplares similares
-
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
por: Mekinian, Arsène, et al.
Publicado: (2023) -
Correction: Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
Publicado: (2019) -
Tocilizumab for faster and safer remission of Takayasu’s arteritis
por: Liao, Hua, et al.
Publicado: (2022) -
Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review
por: Li, Haiyan, et al.
Publicado: (2021) -
Safe use of tocilizumab in pregnant women with Takayasu arteritis: three case studies
por: Konagai, Nao, et al.
Publicado: (2023)